Files
Download Full Text (1.1 MB)
Description
Cancer is the malignant growth and division of abnormal cells. The proliferation of cancerous cells is harmful to the human body since it interferes with many biological processes. Lysine-specific demethylase 1(LSD1) protein levels are expressed at high levels in many types of cancers such as teratocarcinoma, embryonic carcinoma, and embryonic stem cells. Gene expression in cancerous cells can be repressed by lysine-methylation on histones which ensures the maintenance of a tightly organized histone. Targeting LSD1 protein levels can significantly impair the growth of cancer due to the methylated histones being unable to participate in gene expression. Lysine-specific demethylase 1(LSD1) inhibitors prevent the proliferation of cancer by targeting the high concentrations of lysine-specific demethylases vital for cell proliferation. CBB3001 is a LSD1 inhibitor which has been able to inhibit the growth of cancer, warranting further investigation. The aim of this research project is to synthesize CBB3001 by developing efficient synthetic methods and to then create a CBB3001 derivatization library. The researchers involved will synthesize CBB3001, a LSD1 inhibitor, by developing several synthetic pathways with variability along specific steps to produce CBB3001 derivatives. CBB3001, and its derivatives, show great promise in functioning as anti-cancer reagents for many types of human cancers.
Publication Date
Fall 11-15-2021
Language
English
Keywords
LSD1; Anti-cancer; Column; TLC; NMR
File Format
File Size
1000 KB
Recommended Citation
Lopez, Citlally; Huynh, Lilian; and Kang, Jun Yong Ph.D., "Development of Novel Synthetic Methods of Lysine-Specific Demethylase 1(LSD1) Inhibitors as Anti-Cancer Reagents" (2021). Undergraduate Research Symposium Podium Presentations. 19.
https://digitalscholarship.unlv.edu/durep_podium/19
Rights
IN COPYRIGHT. For more information about this rights statement, please visit http://rightsstatements.org/vocab/InC/1.0/
COinS
Comments
Faculty Mentor: Jun Yong Kang, Ph.D.